[Immune Checkpoint Inhibitors for Advanced Melanoma - Evidences and Future Perspectives]

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Advanced melanoma treatment has been revolutionized by immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibodies.
• ICIs demonstrate superior clinical efficacy over traditional chemotherapy, improving response rates, duration of response, and overall survival.
• While generally having fewer adverse events than cytotoxic agents, ICIs can cause severe immune-related adverse events like pneumonia, endocrinopathy, and colitis.

Purpose of the Study:

• To review the efficacy and safety of immune checkpoint inhibitors in advanced melanoma.
• To highlight the need for biomarkers to personalize ICI therapy.
• To explore potential novel combination strategies for improved treatment outcomes.

Main Methods:

• Review of recent clinical trials and studies on immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) in advanced melanoma.
• Analysis of clinical efficacy data, including objective response rates, progression-free survival, and overall survival.
• Evaluation of adverse event profiles and treatment discontinuation rates associated with ICI therapies.

Main Results:

• Anti-PD-1 antibodies significantly improve outcomes in advanced melanoma compared to chemotherapy.
• Combination therapy with anti-PD-1 and anti-CTLA-4 antibodies enhances efficacy but increases adverse events and discontinuation.
• Identification of biomarkers is crucial for predicting patient response, prognosis, and adverse events.

Conclusions:

• Immune checkpoint inhibitors represent a significant advancement in advanced melanoma treatment.
• Personalized treatment selection requires the identification of predictive biomarkers for efficacy and toxicity.
• Future research should focus on novel combination therapies, such as with MAP kinase pathway inhibitors, to further improve clinical responses and survival.